Dacomitinib/Dacomitinib which company is from

Dacomitinib/Dacomitinib (Dacomitinib) is an oral cancer treatment drug produced by the pharmaceutical company Pfizer. Pfizer is a world-renowned pharmaceutical company headquartered in New York, USA. Founded in1849, the company has a long history and rich experience in developing, producing and selling various types of pharmaceuticals around the world. Pfizer is committed to improving people's quality of life through scientific innovation and collaboration to provide patients with better medical solutions.

Dacomitinib is a tyrosine kinase inhibitor that can enhance the inhibitory effect of the epidermal growth factor kinase domain and the activity of drug-resistant mutant cell lines such asT790M. This activity will further significantly reduce phosphorylation and cell viability. Therefore, dacomitinib is often used to treat NSCLC when it has progressed or spread in adults. Dacomitinib is used alone, and only in patients who have a specific mutation in the gene for a protein called epidermal growth factor receptor (EGFR).

The dose of dacomitinib for adults with non-small cell lung cancer is 45 mg/day orally until disease progression or unacceptable toxicity. This is a first-line option for patients with metastatic non-small cell lung cancer who have epidermal growth factor receptor (EGFR) exon 19 or exon 21 L858R substitution mutations. Dosage adjustments may be necessary for special subjects: mild and moderate renal impairment should not be adjusted; dose adjustments have not been studied in severe renal impairment; no dose adjustment is recommended in patients with mild or moderate hepatic impairment.